Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. Gynecol Oncol Rep 2018 Nov;26:91-93
Date
11/15/2018Pubmed ID
30426062Pubmed Central ID
PMC6223187DOI
10.1016/j.gore.2018.10.011Scopus ID
2-s2.0-85055867102 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialysis and a clinically significant disease response was appreciated.